% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

syenfrout 3 posts  |  Last Activity: Jun 16, 2016 9:32 AM Member since: Apr 27, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Anavex 2-73 trial treating Rett syndrome

    by georgejjl Jun 16, 2016 1:41 AM
    syenfrout syenfrout Jun 16, 2016 9:32 AM Flag

    You are correct.

    However, with these rare diseases the trial design can be modified to allow everyone access to the experimental drug.

  • Reply to

    Anavex 2-73 trial treating Rett syndrome

    by georgejjl Jun 16, 2016 1:41 AM
    syenfrout syenfrout Jun 16, 2016 9:05 AM Flag

    Placebo controlled trial for a rare devastating disease?

    I would think recruitment would be difficult if that's the case.

  • Reply to

    Avxl long's best scenario

    by heatherp1114 Apr 30, 2016 3:24 PM
    syenfrout syenfrout May 1, 2016 11:13 AM Flag

    Allergan didn't buy Heptares.

    "Under the terms of the agreement, Heptares will receive an upfront payment of $125 million and is eligible to receive contingent milestone payments of up to approximately $665 million associated with the successful Phase 1, 2 and 3 clinical development and launch of the first three licensed compounds for multiple indications and up to approximately $2.5 billion associated with achieving certain annual sales thresholds during the several years following launch. In addition, Heptares is eligible to receive up to double-digit tiered royalties on net sales of all products resulting from the partnership. Allergan is also committing up to $50 million to a research and development program to be conducted jointly by Allergan and Heptares aimed at advancing multiple candidates through Phase 2 clinical studies. Allergan will be responsible for the development of licensed compounds upon initiation of Phase 2b studies and for subsequent manufacturing and commercialization of the products.

    The agreement covers first-in-class selective small molecule agonists targeting muscarinic M1 and M4 receptors in the brain, discovered using Heptares’ proprietary StaR® technology platform. Allergan will receive exclusive rights to a broad clinical and preclinical portfolio of M1, M4 and dual M1/M4 agonists, including HTL9936 and HTL18318, selective M1 agonists currently in Phase 1 clinical development."

0.3430.000(0.00%)Jul 22 3:59 PMEDT